User profiles for David Montani

David MONTANI

Professor of Respiratory Medicine, Université Paris–Saclay, AP-HP, INSERM UMR_S 999 …
Verified email at aphp.fr
Cited by 33285

[HTML][HTML] Haemodynamic definitions and updated clinical classification of pulmonary hypertension

G Simonneau, D Montani… - European respiratory …, 2019 - Eur Respiratory Soc
Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary
hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) ≥…

[HTML][HTML] Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial

…, P Tissieres, M Jevnikar, D Montani… - JAMA internal …, 2021 - jamanetwork.com
Importance Severe pneumonia with hyperinflammation and elevated interleukin-6 is a common
presentation of coronavirus disease 2019 (COVID-19). Objective To determine whether …

Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era

…, E Hachulla, V Cottin, B Degano, X Jaïs, D Montani… - Circulation, 2010 - Am Heart Assoc
Background— Novel therapies have recently become available for pulmonary arterial
hypertension. We conducted a study to characterize mortality in a multicenter prospective cohort of …

Four-month clinical status of a cohort of patients after hospitalization for COVID-19

…, B Wyplosz, M Zaidan, L Becquemont, D Montani… - Jama, 2021 - jamanetwork.com
Importance Little is known about long-term sequelae of COVID-19. Objective To describe
the consequences at 4 months in patients hospitalized for COVID-19. Design, Setting, and …

[HTML][HTML] A novel channelopathy in pulmonary arterial hypertension

…, EB Rosenzweig, B Girerd, D Montani… - … England Journal of …, 2013 - Mass Medical Soc
Background Pulmonary arterial hypertension is a devastating disease with high mortality.
Familial cases of pulmonary arterial hypertension are usually characterized by autosomal …

Pulmonary arterial hypertension in patients treated by dasatinib

D Montani, E Bergot, S Günther, L Savale, A Bergeron… - Circulation, 2012 - Am Heart Assoc
Background— The French pulmonary hypertension (PH) registry allows the survey of
epidemiological trends. Isolated cases of precapillary PH have been reported in patients who have …

EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension

M Eyries, D Montani, B Girerd, C Perret, A Leroy… - Nature …, 2014 - nature.com
Pulmonary veno-occlusive disease (PVOD) is a rare and devastating cause of pulmonary
hypertension that is characterized histologically by widespread fibrous intimal proliferation of …

[HTML][HTML] Sotatercept for the treatment of pulmonary arterial hypertension

…, J Feldman, G Meyer, D Montani… - … England Journal of …, 2021 - Mass Medical Soc
Background Pulmonary arterial hypertension is characterized by pulmonary vascular
remodeling, cellular proliferation, and poor long-term outcomes. Dysfunctional bone …

Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension

…, A Bourdin, F Parent, D Montani… - European …, 2017 - Eur Respiratory Soc
Current European guidelines recommend periodic risk assessment for patients with
pulmonary arterial hypertension (PAH). The aim of our study was to determine the association …

Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?

A Huertas, D Montani, L Savale… - European …, 2020 - Eur Respiratory Soc
Coronavirus disease 2019 (COVID-19) represents a public health crisis of pandemic
proportions. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the …